APA

Knop S., Hebart H., Gscheidle H., Holler E., Kolb H., Niederwieser D. & Einsele H. (20060110). OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. : Bone marrow transplantation.

Chicago

Knop S, Hebart H, Gscheidle H, Holler E, Kolb H-J, Niederwieser D and Einsele H. 20060110. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. : Bone marrow transplantation.

Harvard

Knop S., Hebart H., Gscheidle H., Holler E., Kolb H., Niederwieser D. and Einsele H. (20060110). OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. : Bone marrow transplantation.

MLA

Knop S, Hebart H, Gscheidle H, Holler E, Kolb H-J, Niederwieser D and Einsele H. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. : Bone marrow transplantation. 20060110.